US2021128514A1PendingUtilityA1

Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker

Assignee: DR KENNETH ADAMS MEDICINE PROFESSIONAL CORPPriority: Dec 3, 2009Filed: Jan 11, 2021Published: May 6, 2021
Est. expiryDec 3, 2029(~3.3 yrs left)· nominal 20-yr term from priority
A61P 31/22A61K 31/554A61K 31/277A61K 31/5415A61P 11/00A61K 31/00A61P 37/00A61P 37/08A61K 31/4422A61P 31/12A61P 31/04
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

In the broadest aspect, the invention provides a composition for and a method of prophylactic and/or therapeutic treatment of a animal/mammal for any viral disease, mixed bacterial and viral infections, bacterial infections, bacterial endotoxins, bacterial exotoxins, autoimmune diseases, and cellular or humoral mediated allergic conditions that is caused by any virus that relies on the maintenance of specific calcium ion concentrations for the post ribosomal RNA synthesis processing of viral protein translation, transportation and processing of viral structural components by utilizing a therapeutic amount of a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, of calmodulin blocker and a metabolite thereof, and a pharmaceutical acceptable diluent or carrier, and/or is caused by damage to the animal/mammal by a pathological immune response to antigens.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A pharmaceutical composition for treatment and prevention of broad spectrum virus ailments comprising a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof, and a pharmaceutical acceptable diluent or carrier. 
     
     
         2 . A composition as claimed in  claim 1 , wherein said calcium channel blocker is verapamil. 
     
     
         3 . A composition as claimed in  claim 1 , wherein said calcium channel blocker is diltiazem. 
     
     
         4 . A composition as claimed in  claim 1 , wherein said calcium channel blocker is felodipine. 
     
     
         5 . A composition as claimed in  claim 1 , wherein said calmodulin blocker is trifluoperazine. 
     
     
         6 . A composition as claimed in any one of  claims 1  to  5 , wherein said composition is in the form of a cream, spray, mouth wash, gel, ointment or patch. 
     
     
         7 . A composition as claimed in any one of  claims 1  to  5 , wherein said composition is in the form of a tablet, a sustained release formulation for systemic use. 
     
     
         8 . A composition as claimed in any one of  claims 1  to  5 , wherein said composition is in the form of a sterile solution for parenteral injection. 
     
     
         9 . A method for the treatment and prevention of broad spectrum virus ailments comprising administering to a human being a composition comprising a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof, and a pharmaceutical acceptable diluent or carrier. 
     
     
         10 . A method as claimed in  claim 9 , wherein said calcium channel blocker is verapamil. 
     
     
         11 . A method as claimed in  claim 9 , wherein said calcium channel blocker is diltiazem. 
     
     
         12 . A method as claimed in  claim 9 , wherein said calcium channel blocker is felodipine. 
     
     
         13 . A method as claimed in  claim 9 , wherein said calmodulin blocker is trifluoperazine. 
     
     
         14 . A method as claimed in  claim 9 , wherein said administration comprises subcutaneous injection, high pressure jet device, intracavernous injection, intravenous injection, intramuscular injection, intradermal injection, intra-nasal or topical administration. 
     
     
         15 . A method as claimed in  claim 12 , wherein said administration is topical administration. 
     
     
         16 . A method of manufacturing a medicament intended for the application of treating and preventing broad spectrum virus ailments characterized in that said medicament comprises a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof; and admixed with a pharmaceutical acceptable diluent or carrier. 
     
     
         17 . A method as claimed in  claim 16 , wherein said blocker is selected from verapamil, diltiazem, felodipine and trifluoperazine.

Join the waitlist — get patent alerts

Track US2021128514A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.